The Focus of This Study is to Evaluete the Significances of the Vagal Cholinerg Nervuos System for the Effect of GLP-1 by Using Atropin Administration.
Conditions
Brief summary
The aim of this study is to investigate the role of transmission of vagal cholinerg for the GLP-1 potentiation of the glucose stimulated insulin secretion and the cephalic insulin response by using atropin administration. The hypothesis is that a great deal of the effects of GLP-1 is mediated via the nervous system and for this reason the investigators will research individuals with an intact nervous supply with and without atropin administration.
Detailed description
GLP-1 is a importent enterogastron and incretin hormone. Rapid degradation of GLP-1 by dipeptidyl peptidase 4 (DPP-4) suggests that GLP-1 may act locally (through vagal afferents) before being degraded. We aimed to clarify the role of vagal innervation on the incretin effect.
Interventions
DRUGAtropine
1 mg as a bolus and the and infusion of 80 ng/kg/min for either 105 or 145 minuts.
DRUGPlacebo
Sponsors
University of Copenhagen
University Hospital, Gentofte, Copenhagen
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* age between 18 and 45 years * normal fasting plasma glucose * normal hemoglobin * informed consent
Exclusion criteria
* diabetes mellitus * body mass index above 30 * inflamatoric bowel disease * intestinal surgery * serum creatinine above 250 microM * ALAT above to times normal value * treatment with medicine wich cannot be paused for 12 hours * contraindication for treatment with atropin
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| insulin secretion | tree hours | The insulin secretion during lightly elevated blood glucose during GLP-1 infusions with and without atropin administration is evaluated. Also the insulin secretion during lightly elevated blood glucose during a sham-feeding with and without atropin administration is evaluated. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plasma glucose | 30 within tree hours | 30 blood samlpes will be drawn during lightly elevated blood glucose during a sham-feeding with and without atropin administration. |
| Plasma GLP-1 | 20 time points within tree hours | 20 blood samlpes will be drawn during lightly elevated blood glucose during a sham-feeding with and without atropin administration. |
| Plasma PP | 20 time points within tree hours | 20 blood samlpes will be drawn during lightly elevated blood glucose during a sham-feeding with and without atropin administration. |
| Plasma GIP | 18 timepoints within tree hours | 18 blood samples will be drawn during lightly elevated blood glucose during GLP-1 infusions with and without atropin administration. |
| Plasma glucagon | 18 timepoints within tree hours | 18 blood samples will be drawn during lightly elevated blood glucose during GLP-1 infusions with and without atropin administration. |
| Plasma GLP-2 | 18 time points within tree hours | 18 blood samples will be drawn during lightly elevated blood glucose during GLP-1 infusions with and without atropin administration. |
Countries
Denmark
Contacts
Primary ContactAstrid Plamboeck, MD
Outcome results
None listed